Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Acquisitions (2016 - 2018)

Historic Acquisitions for Integra Lifesciences Holdings (IART) over the last 10 years, with Q4 2018 value amounting to -$53.4 million.

  • Integra Lifesciences Holdings' Acquisitions fell 10525.47% to -$53.4 million in Q4 2018 from the same period last year, while for Sep 2023 it was -$53.4 million, marking a year-over-year change of. This contributed to the annual value of $30.5 million for FY2019, which is 21424.88% up from last year.
  • Integra Lifesciences Holdings' Acquisitions amounted to -$53.4 million in Q4 2018, which was down 10525.47% from $21.0 million recorded in Q2 2018.
  • In the past 5 years, Integra Lifesciences Holdings' Acquisitions ranged from a high of $1.0 billion in Q4 2017 and a low of -$53.4 million during Q4 2018
  • For the 5-year period, Integra Lifesciences Holdings' Acquisitions averaged around $124.3 million, with its median value being $20.6 million (2015).
  • The largest annual percentage gain for Integra Lifesciences Holdings' Acquisitions in the last 5 years was 22596533.33% (2017), contrasted with its biggest fall of 1930000.0% (2017).
  • Over the past 5 years, Integra Lifesciences Holdings' Acquisitions (Quarter) stood at $85.9 million in 2014, then crashed by 75.99% to $20.6 million in 2015, then tumbled by 102.18% to -$450000.0 in 2016, then skyrocketed by 225965.33% to $1.0 billion in 2017, then plummeted by 105.25% to -$53.4 million in 2018.
  • Its Acquisitions stands at -$53.4 million for Q4 2018, versus $21.0 million for Q2 2018 and $5.7 million for Q1 2018.